Allogene Therapeutics, Inc. Quarterly Depreciation in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Allogene Therapeutics, Inc. quarterly/annual Depreciation history and growth rate from Q1 2019 to Q1 2024.
  • Allogene Therapeutics, Inc. Depreciation for the quarter ending March 31, 2024 was $3.56M, a 1.37% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Depreciation for 2023 was $14.2M, a 0.67% decline from 2022.
  • Allogene Therapeutics, Inc. annual Depreciation for 2022 was $14.3M, a 36.7% increase from 2021.
  • Allogene Therapeutics, Inc. annual Depreciation for 2021 was $10.5M, a 40.6% increase from 2020.
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $3.56M +$48K +1.37% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q1 2023 $3.51M -$185K -5.01% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q1 2022 $3.69M +$1.77M +92.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q1 2021 $1.92M +$25K +1.32% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 $1.89M +$1.35M +248% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q1 2019 $544K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.